Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success
Shifts Focus To Earlier Program
Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.
You may also be interested in...
Novo Holdings CEO Kasim Kutay discusses today’s financing challenges and tomorrows big pharma pipeline problems in an exclusive interview. Despite turbulent times, he is positive about the future of health care.
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.